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Abstract 
CD4+ T cells recognize antigens through their T cell receptors (TCRs); however, additional signals 
involving co-stimulatory receptors, for example CD28, are required for proper T cell activation. 
Alternative co-stimulatory receptors have been proposed, including members of the Toll-like 
receptor (TLR) family, such as TLR5 and TLR2. To understand the molecular mechanism 
underlying this co-stimulatory function, we generated detailed molecular maps and logical models 
for the TCR and TLR5 signaling pathways, together with a merged model accounting for cross-
interactions. Furthermore, we validated the resulting model by analyzing the responses of T cells 
to the activation of these pathways alone or in combination, in terms of the activation of the 
transcriptional regulators CREB, AP-1 (c-Jun), and NF-B (p65). Our merged model accurately 
reproduces the experimental results, showing that the activation of TLR5 can play a similar role 
to that of CD28 activation with respect to AP-1, CREB, and NF-кB activation, thereby providing 
insights regarding the cross-regulation of these pathways in CD4+ T cells. 
 
 Introduction 
Antigens are presented to CD4+ T cells by specialized antigen-presenting cells (APCs), such as 
dendritic cells, through major histocompatibility complex (MHC) class II molecules. CD4+ T cells 
recognize the antigens through their T cell receptors (TCRs) (1–4). These cells also receive signals 
through the co-receptor CD4, co-stimulatory receptors, such as CD28, and through other 
stimulatory and inhibitory accessory receptors (5–7). These receptors sense the cytokines and other 
molecules in the microenvironment surrounding the cells and on the surface of the APCs. T cells 
integrate these signals, which results in their activation and differentiation into specialized effector 
cells (7–11). CD4+ T cells coordinate the adaptive immune response through cell-to-cell contacts 
and the secretion of cytokines that influence the activity of other cell types. TCR signaling has 
been a major research topic during the last decade, in particular with a view to identifying new 
targets to inhibit, enhance, or alter the outcome of T cell activation. However, an updated 
comprehensive version of this crucial pathway is missing. In recent years, new, high-throughput 
technologies have enabled substantial advances in the field, revealing an unprecedented level of 
complexity of TCR signaling (12–18). 
 
TCR-mediated signaling can be divided in four main modules: (i) early signaling, which is 
characterized by the recruitment and phosphorylation of Lck (Lymphocyte cell-specific protein-
tyrosine kinase); (ii) the formation of signalosome complexes containing LAT (Linker for 
activation of T-cells), CD6 (T-cell differentiation antigen CD6), or both; (iii) the activation of 
important mediators such as protein kinase C  (PKC); and (iv) downstream signaling through 
mitogen-activated protein kinases (MAPKs), inhibitor of nuclear factor kappa-B kinases (IKKs) 
kinases, and Ca2+-mediated signaling (19–22). TCR signaling results in the activation of inducible 
 transcription factors, which in turn promote changes in gene expression. The main transcription 
factors that mediate TCR-inducible gene expression are: NFAT (Nuclear Factor of Activated T 
cells), NF-кB (Nuclear Factor kappaB), AP-1 (Activator protein 1), and CREB (cAMP Response 
Element Binding) (20, 23–28). A proper balance between the activation of these transcription 
factors leads to robust T cell activation and differentiation, whereas imbalances may induce an 
impaired immune response, which can result in anergy or apoptosis (4, 29–32). For example, NF-
B and NFAT are both members of the Rel family of transcription factors and may compete for 
binding motifs on DNA targets. A balance between NFAT and NF-B affects the phenotype of 
the cells. When NF-B activity is greater than that of NFAT, the cell exhibits a proinflammatory 
response, whereas the absence of NF-B activity leads to an anti-inflammatory response (33–36). 
Other transcription factors that respond to TCR activation include β-catenin (37, 38) and serum 
response factor (SRF) (39). 
 
T cell activation takes place in the lymph nodes where, in addition to the signals provided by APCs, 
pieces of antigens and molecules secreted by other cells circulate. Among these, the flagellin 
monomer is directly recognized by CD4+ T cells through the cell-surface receptor TLR5 (40, 41). 
TLRs are important modulators of the cellular response and triggering their activation through 
appropriate vaccine adjuvants is a promising therapeutic approach. TLR expression, signaling, and 
function have been characterized in cells of the innate immune system (42–45). TLR signaling is 
initiated by ligand binding, dimerization of receptors, and recruitment of the adaptor proteins 
MyD88 (Myeloid differentiation primary response protein MyD88) or TRIF (Toll-interleukin-1 
receptor domain-containing adapter inducing interferon beta). With the exception of TLR3, all 
TLRs recruit MyD88, whereas TLR3, TLR4, and TLR5 recruit TRIF. These adaptors induce the 
 sequential recruitment and activation of a series of kinases of the IRAK (Interleukin-1 receptor-
associated kinase) family, leading to the activation of IKKs and MAPKs (45–48). The activation 
of TLRs can also stimulate the phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) pathway, 
leading to the activation of the transcription factors AP-1 and CREB (49–51). Together, 
downstream of TLR signaling, NF-кB, AP-1, and CREB are activated. When TLRs recruit TRIF, 
members of the interferon response factor (IRF) family of transcriptional regulators are also 
activated (52, 53). 
 
Flagellin, a component of the flagella of many bacteria and a ligand of TLR5, has been proposed 
as a vaccine adjuvant for its ability to induce a proinflammatory response in several cell types (54–
57). Although classically studied for its function in cells of the innate immune system, TLR5 is 
one of the main TLRs expressed in T cells. In CD4+ T cells, TLR5 function is not well 
characterized, but it was reported that TLR5 co-stimulatory signals can induce proliferation and 
expression of cytokines, such as interferon- γ (IFN-γ) (58). Moreover, CD4+ and CD8+ T cells 
respond to TLR5 co-stimulatory signals (59, 60). 
 
To better understand the role of TCR signaling network in the activation of key transcription 
factors, focusing in particular on the interplay between TCR and TLR5-mediated signaling, we 
have used two complementary computational approaches to generate (i) detailed molecular maps 
of the TCR and TLR5 pathways, and (ii) predictive qualitative models of the dynamical behavior 
of these pathways, taking into account documented cases of cross-talk. To build and refine these 
models, we took advantage of the RNA-seq and ChIP-seq data generated by the BLUEPRINT 
consortium (http://www.blueprint-epigenome.eu/). Furthermore, we evaluated the activation of c-
 Jun, p65, and CREB upon engagement of the TCR in the absence or presence of the TLR5 ligand, 
flagellin. Model predictions were systematically compared with experimental data to refine and 
validate our models. Our combined experimental and modeling analyses indicate that TLR5 is a 
co-stimulatory receptor of the TCR, with an effect on cell activation comparable to that of CD28. 
 
Results 
Generation of a molecular map and a logical model for the TCR pathway 
We collected information from public databases, in particular Reactome and KEGG, and curated 
the literature to construct a molecular map describing the TCR signaling network (Fig. S1 and File 
1). Using the software GINsim (http://ginsim.org), we then built a detailed logical model 
describing TCR-mediated signaling in CD4+ T cells, taking as starting point the model published 
by Sáez-Rodriguez et al (61), and substantially updating it with data previously integrated in the 
molecular map. We used mainly data from primary human and mouse CD4+ T cells, which were 
completed with information from human CD8+ T cells, as well as from Jurkat cells and other cell 
lines, assuming that key signaling events are conserved between T cells, and furthermore between 
mice and humans. The model nevertheless keeps track of the origin of the information (cell lines, 
species, and bibliographical entries) in the annotations associated with each component. To ensure 
that all model components were effectively expressed in CD4+ T cells, we checked their expression 
using public RNA-seq and ChIP-seq data (Table S1 and Materials and Methods). The resulting 
TCR-mediated signaling model encompasses 110 nodes (Fig. 1 and File 2). In particular, TCR and 
CD28 correspond to the canonical receptors that initiate the activation of CD4+ T cells (represented 
by green nodes in Fig. 1). Other nodes, such as CD4, CD45, CD6, RCAN1, and Akap5, correspond 
to model inputs for which we considered a default value of 1 or 0 (see Table S5). In vivo, TCR 
 signals are provided by an antigenic peptide presented by APCs in association with MHCII 
molecules. CD4 recognizes the MHCII molecule itself, and CD28 recognizes the co-stimulatory 
molecules (CD80 and CD86) expressed in activated APCs. 
 
We included the key transcription factors NF-кB (NFkB in the model and in Fig. 1), AP-1 (AP1), 
NFAT (NFAT), CREB (CREB1), SRF (SRF) and β-catenin (CTNNB1) (Fig. 1, yellow nodes). A 
combination of these transcription factors regulates most of the effector genes expressed during 
CD4+ T cell activation. To facilitate interpretation, we further explicitly included phenotypic nodes 
(Fig. 1, output nodes in gray) representing functional responses: proinflammatory cytokines 
(PICytokines), anti-inflammatory cytokines (AICytokines), cell cycle progression 
(CellCycleProg), survival (Survival), cytoskeleton re-arrangement (ActinRem), and anergy 
(Anergy). The model was then completed by assigning a logical rule to each node (Table S2). 
These logical rules describe how the activation status of each node is determined by the amounts 
of its regulators (see Materials and Methods). We computed the stable states of the TCR model 
and compared them with the experimental behavior of the TCR pathway as reported in the 
literature. Observed discrepancies led us to refine the model rules (see Supplementary Text) until 
a reasonable qualitative match was obtained (see Fig. 2). For example, stimulation of the TCR 
alone induces NFAT activation and a state of anergy, whereas stimulation of both the TCR and 
CD28 induces the activation of NFAT, NF-кB, AP-1, and CREB, promoting cytoskeleton re-
arrangement, survival, cell cycle progression, and the expression of pro- and anti-inflammatory 
cytokines. Next, we assessed the behavior of our model in the context of either knockout or 
inhibition of PI3K (PI3K) or PKCθ (PKCth). The model correctly reproduces several scenarios. 
First, when only TCR signals are present (without co-stimulation), a state of anergy is reached, 
 which is characterized by the activation of NFAT and the lack of AP-1 and NF-кB activation. 
Second, when both the TCR and CD28 are stimulated, all six transcription factors are activated. 
Third, when PI3K activity is impaired, the activation of AP-1 and NF-кB is compromised (which 
would lead to anergy). This occurs because PI3K contributes to the activation of NF-кB (62) and 
AP-1 (63). Fourth, our model accounts for the fact that NF-кB cannot be activated by TCR signals 
(either alone or in combination with CD28 signals) when PKCθ is impaired, due to the lack of 
proper activation of IKK (23, 64). In this case, our model predicts that the production of 
proinflammatory cytokines, cell cycle, and survival, for which NF-кB is essential, would be 
affected when this transcription factor is not activated, but that the production of anti-inflammatory 
cytokine would be unaffected. 
 
Generation of a molecular map and a logical model for TLR5 pathway 
Similarly, to study the role of TLR5 signaling in naïve CD4+ T cells, we generated a detailed 
molecular map (Fig. S2 and File 3) and a logical model (Fig. 3 and File 4) for this pathway. Our 
TLR5 logical model encompasses 42 nodes, including one input component, TLR5, which is 
activated by flagellin. The model further includes the transcription factors NF-кB (NFkB), AP-1 
(AP1), and CREB (CREB1), together with three phenotypic (output) nodes representing 
proinflammatory cytokines (PICytokines), anti-inflammatory cytokines (AICytokines), and cell 
survival (Survival). As for the TCR model, we used transcriptomic and epigenetic data from 
BLUEPRINT consortium (Table S1) to verify the expression of the signaling molecules. We kept 
only those components associated with active enhancers (H3K4me1 and H3K27ac marks) and/or 
active promoters (H3K4me3 and H3K27ac marks), together with statistically significant gene 
expression as reported in the RNA-seq data (Fig. S3). Finally, a logical rule was assigned to each 
 node of the TLR5 regulatory graph (Table S3) as for the TCR model (see Materials and Methods). 
To challenge our TLR5 model (Fig. 3), we compared model simulations with published 
experimental data for the wild-type situation, as well as for TAK1 and PI3K knockouts (Fig. 4). 
The simulation of the TAK1 KO resulted in the loss of activation of NF-кB, AP-1, and CREB, as 
observed previously (49, 65–68). Similarly, simulation of the PI3K KO resulted in the impairment 
of NF-кB, AP-1, and CREB activation, consistent with previous studies (62, 63, 69, 70). 
 
Cooperation between TCR and TLR5 signals for T cell activation 
To analyze the interactions between TCR and TLR5 pathways and their role in T cell activation, 
we merged our TCR and TLR5 models using the GINsim software (Fig. 5, Table S4 and File 5). 
Our merged model encompasses 128 nodes, including three externally controlled inputs (TCR, 
CD28, and TLR5) and six phenotypic (output) nodes. Although both receptors coincide in the 
activation of common transcription factors, the signaling pathways leading to transcription factor 
activation are mostly independent. 
 
Next, we computed the stable states of the resulting model for wild-type and mutant backgrounds 
and adjusted the rules of the components lying at the intersection between the two original models 
to consider all regulatory inputs and to be consistent with the experimental data (Fig. 6; see the 
Supplementary Text for more details on the adjustment of the logical rules). Taking advantage of 
a model reduction functionality implemented in GINsim (see Materials and Methods), we 
generated a simpler, but dynamically consistent, version of the merged “TCR+TLR5” model, 
which conserves all critical nodes and interactions (Fig. S4). The reduced merged model 
encompasses 59 components. This model was then used to simulate T cell activation by different 
 combinations of signals. According to these simulations, TLR5 signals induce the activation of the 
PI3K, NF-кB, and MAPK pathways (Fig. 4). We hypothesized that this activation process could 
synergize with TCR signals to induce a productive activation of naïve CD4+ T cells. 
 
Experimental validation of the merged TCR and TLR5 model 
To challenge our merged TCR+TLR5 model, we studied the response of naïve CD4+ T cells to 
stimulation of the TCR alone, of TLR5 alone, of the TCR together with TLR5, and of the TCR 
together with CD28, in strong and weak activation conditions, and assessed the phosphorylation 
of p65, c-Jun, and CREB1. As strong stimulus, we used a high concentration (1 µg/ml) of each 
anti-CD3 and anti-CD28 antibody crosslinked with a goat anti-mouse antibody, as reported by 
others (71–75). We further used a lower concentration (0.1 µg/ml) of each antibody to achieve a 
weak or suboptimal stimulation (74–77). Although all the evaluated molecules showed a basal 
level of phosphorylation, statistically significantly greater phosphorylation was achieved when the 
cells were exposed to strong stimuli of TCR alone (for CREB activation), or of TCR and co-
stimulatory signals (for p65 and c-Jun) (Fig. 7). Weak signals by the TCR or costimulatory 
molecules in different combinations resulted in wide variations in the extent of p65 and c-Jun 
activation, suggesting that signaling strength must exceed a threshold to result in robust activation 
of the cell population, which only under strong TCR stimulation and co-stimulation was 
reproducible in every biological sample. Furthermore, the combination of TCR and TLR5 
stimulation gave rise to a similar response to that induced by costimulation of the TCR and CD28. 
Together, our experimental results thus suggest the potential of flagellin to provide co-stimulatory 
signals directly to T cells, as predicted by our logical simulations. 
 
 Discussion 
We generated detailed molecular maps and logical models for TCR and TLR5 signaling pathways, 
which were adapted to human naïve CD4+ T cells, taking into account the expression and 
epigenetic status of the main genes involved. These models were fine-tuned until reaching a 
behavior in agreement with experimental data, including four documented perturbations. These 
models were then merged to generate a combined “TCR + TLR5” model, which was used to 
predict the activation of key transcription factors upon induction of each or both pathways. 
Simulation results were compared with experimental results regarding the activation of c-Jun (AP-
1), CREB, and p65 (NF-κB). Our simulations and experimental results point to a potential role of 
TLR5 co-stimulatory signals in the activation and differentiation of CD4+ T cells through the 
induction of AP-1, CREB, and NF-кB activation, which can in turn induce (directly or through 
other transcription factors) the expression of several genes encoding cytokines, receptors, and 
signaling molecules. 
 
According to our modeling and experimental results, the TLR5 pathway cooperates with TCR 
signals to induce NF-кB and AP-1 activation. This could explain the role of TLR5 in the 
proliferation of CD4+ T cells, as well as the production of the cytokines IFN-γ and IL-8 (58). 
However, although both the TCR and TLR5 resulted in the activation of common transcription 
factors, the signaling pathways leading to transcription factor activation were mostly independent. 
This suggests that the TLR5 pathway could act as a rescue pathway to enable CD4+ T cell 
activation in immunodeficient conditions, for example, when important signaling molecules of the 
TCR pathway are inactive or inadequately functioning. In this respect, we previously recently 
reported (78) that TLR5 signals play a proinflammatory role in neonatal and adult CD4+ T cells, 
 leading to the production of IFN- Thus, TLR5 contributes to overcome the higher activation 
threshold of neonatal CD4+ T cells, which are characterized by defective TCR/CD28–mediated 
AP-1 activation (79). Consistent with this finding, flagellin is a good adjuvant, inducing protection 
in a neonatal mouse vaccination model of rotavirus infection (78). 
 
In summary, combining computational modeling and experimental validations, our combined 
experimental and modeling analysis demonstrates that TLR5 is a co-stimulatory receptor for CD4+ 
T cells, and that it uses a different pathway than that used by CD28 to induce the activation of the 
transcription factors NF-кB and AP-1. This function of TLR5 is independent of its role in innate 
immunity, because our experiments were performed with isolated, naive CD4+ T cells. However, 
both functions of TLR5 might be important for a full immune response in vivo. 
 
Materials and Methods 
Generation of molecular maps 
We generated detailed molecular maps for the TCR and TLR5 signaling pathways using the 
software CellDesigner (http://www.celldesigner.org/). To do this, we relied on data gathered from 
the literature and from databases such as KEGG (http://www.genome.jp/kegg/), Reactome 
(http://www.reactome.org/), and DC-ATLAS (http://compbiotoolbox.fmach.it/DCATLAS.php). 
In CellDesigner, there are three possible types of Components, which are Species, Reactions, and 
Compartments. A Species represents a protein, a complex, or some other molecule in a 
biochemical or regulatory network. On the other hand, a Reaction can be a chemical reaction, a 
physical interaction between Species, or a regulatory relation between genes. Finally, a 
Compartment represents a container for other components, such as a cell or an intracellular 
 compartment. All species and reactions of the molecular maps are annotated with textual 
comments and hyperlinks to record the supporting information and its source (see Files 1 and 3).  
 
Generation of logical models 
We built our logical models using the software GINsim (www.ginsim.org), relying on the 
molecular maps previously generated. GINsim implements the multivalued logical modeling 
formalism introduced by Thomas and D’Ari (80). This formalism relies on the delineation of a 
regulatory graph (LRG), where each component (protein or more abstract biological function) is 
represented by a logical node (taking the values 0 or 1, or additional values when justified), and 
each influence (activation or inhibition) between a pair of components is represented by a signed 
arc. Next, a logical rule is assigned to each node in the network, which determines its activation 
level according to the levels of its regulators. These logical rules involve literals (component 
values) and the logical operators AND, OR and NOT (81, 82). We confirmed the expression of all 
model components in unstimulated naïve CD4+ T cells using RNA-seq and ChIP-seq data reported 
by the BLUEPRINT consortium (Table S1). A gene was considered expressed if it could be 
associated with regions with chromatin marks denoting active promoters or enhancers, together 
with an expression value of at least 1 RPKM (Reads Per Kilobase of transcripts, per Million 
mapped). ChIP-seq peaks of histone modifications were given as input to the software 
ChromHMM (http://compbio.mit.edu/ChromHMM/) (with the parameters BinerizeBed –center 
option, assembly hg38; LearnModel 10 states) to segment the genome in different regions 
according to their chromatin states. We then selected the regions associated with marks of active 
promoters (H3K4me3+H3K27ac+) and enhancers (H3K4me1+H3K27ac+). 
 
 Model analysis 
The two original models for the TCR and TLR5 signaling pathways were merged and the logical 
rules of shared nodes were updated to take into account the additional regulatory inputs (Fig. 5, 
Table S4, and File 5). We computed the stable states of the two original and merged models under 
wild-type and mutant conditions. We further generated a reduced version of the merged model 
(Fig. S4) to explore its dynamical behavior. All of the analyses were performed with GINsim [as 
previously described (81–84)], which supports model reduction by hiding selected (intermediate) 
nodes. Provided that no functional regulatory circuit is eliminated in the process, this reduction 
preserves all attractors (81). The dynamical behavior of a logical model is represented by a State 
Transition Graph (STG). In this graph, each node represents a state of the model, which is defined 
by a vector encompassing the levels of all components, and the arcs represent transitions between 
states. One core function of GINsim is the automatic construction of this graph (82). When the 
number of components in a model is large, the resulting STG becomes difficult to compute and to 
visualize. In this respect, GINsim enables the generation of a Hierarchical Transition Graph 
(HTG), which is computed by clustering the nodes of a STG into groups of states (hyper-nodes) 
sharing the same set of successors (84). Finally, computing the HTG for different initial conditions 
enabled us to identify all of the attractors of our merged model for wild-type and mutant scenarios 
(see Results). 
 
Cell isolation and culture 
Leukocyte concentrates were obtained from healthy donors from the “Centro Estatal de la 
Transfusión Sanguínea”, Cuernavaca, Mexico. Peripheral blood mononuclear cells (PBMCs) were 
obtained from these cellular concentrates through centrifugation with ficoll-hypaque gradient. 
 Total CD4+ T cells were obtained using the RosetteSep CD4+ T cell enrichment cocktail (Stem 
Cell) and 1 ml of erythrocytes from the same donor. We depleted memory cells with an anti-
CD45RO antibody (Tonbo) coupled to magnetic beads (Pierce) with the help of a magnetic rack. 
Naive CD4+ T cells obtained this way were cultured in RPMI medium supplemented with 5% fetal 
bovine serum (FBS) at 37°C with 5% CO2. Cell preparations were routinely checked for purity and 
were at least 96% CD3+CD4+, CD45RO-, and 96% CCR7+CD62L+. 
 
CD4+ T cell stimulation 
Naive CD4+ T cells were either left unstimulated or stimulated by cross-linking the CD3 receptor 
(simulating TCR ligation), with flagellin (to activate TLR5), with both stimuli (TCR + TLR5 
activation), or by cross-linking CD3 and CD28 (TCR + CD28 activation). The activation of the 
following molecules was evaluated by flow cytometry: p65 (pp65), CREB (pCREB), c-Jun (pc-
Jun). Cells were stimulated in RPMI medium supplemented with 2% FBS. The following 
antibodies were used at 1 µg/ml and 0.1 µg/ml in different combinations: anti-CD3 (OKT3) 
(Tonbo) antibody, anti-CD28 (CD28.2) (Tonbo) antibody, and polyclonal goat anti-mouse 
antibody (Biolegend) to crosslink the anti-CD3 and anti-CD28 antibodies. TLR5 signals were 
induced with flagellin monomer (Invivogen) at final concentrations of 250 or 25 ng/ml. 
 
Flow cytometry 
To evaluate the purity of cell preparations, the following markers were evaluated by extracellular 
staining: CD3, CD4, CD45RO, CD45RA, CCR7, and CD62L. This consisted of the incubation of 
cells with antibody solutions for 30 min at 4°C, washing with PBS supplemented with 2% FBS, 
and a fixation step with 1% formaldehyde. The following antibodies were used: anti-CD3-PE 
 (Tonbo), anti-CD4-APC (Biolegend), anti-CD62L-PE (Miltenyi), anti-CCR7-FITC (Miltenyi), 
anti-CD45RO-FITC (Tonbo), and anti-CD45RA-FITC (Miltenyi). The activation of p65, CREB, 
and c-Jun was evaluated by intracellular staining. This consisted of the fixation of cells with 1.5% 
formaldehyde for 10 min, a permeabilization step with cold absolute MeOH for 10 min (0°C) or 
more (-80°C), a washing step with PBS supplemented with 2% FBS, incubation with antibody 
solution for 30 min at 4°C, and another washing step together with a final fixation step with 1% 
formaldehyde Activations of p65, c-Jun and CREB were evaluated by flow cytometry. Activation 
was determined by evaluating the phosphorylated protein in specific reported residues. We used 
anti-pc-Jun (Ser63) (Genetex), anti-pCREB (Ser133) (Pierce), a secondary anti-rabbit-FITC 
(Genetex) and anti-pp65 (Ser529)-APC (Miltenyi Biotec) antibodies. A FACScanto II (BD 
Biosciences) cytometer was used and data analysis was performed using the FlowJo software (Tree 
Star Ca). Changes of activated protein levels across pairs of  conditions were assessed using 
Kruskal-Wallis tests and the software GrahPad Prism 7 (Tables S6, S7 and S8). 
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 Figures. 
 
Fig. 1. The TCR signaling model. The model encompasses 110 nodes, including two externally 
controlled inputs (TCR and CD28), which are depicted in green, six activated transcription factors, 
which are in yellow, and six phenotypical outputs, which are in gray. Green arrows represent 
activation events, whereas red blunt-end arcs denote inhibition events. PICytokines, 
proinflammatory cytokines; AICytokines, anti-inflammatory cytokines. 
 
 
 
  
Fig. 2. Computation of the stable states of the TCR model. The rows list the stable states 
identified with GINsim software for three distinct scenarios [Wild-type (WT), PKCθ KO, and 
PI3K KO) and three environmental conditions (Unstimulated, TCR stimulation, or TCR + CD28 
stimulation). Note that only the relevant nodes are displayed. White cells (zero value) denote 
negligible activation of the corresponding components (columns), whereas blue cells (value of 1) 
denote substantial activation. Inputs are highlighted in green, phenotypical nodes are in gray, and 
the transcription factors induced during T cell activation are in yellow. CellCycleProg, cell cycle 
progression; ActinRem, actin remodeling. 
 
 
 
 
 
  
Fig. 3. The TLR5 signaling model. The model encompasses 42 nodes, among which one 
corresponds to the TLR5 input (green), three correspond to key three transcription factors (yellow), 
and three to phenotypical output nodes (gray). Green arrows represent activation events, whereas 
red blunt-end arcs denote inhibition events. 
 
 
 
 
  
Fig. 4. Computation of the stable states of the TLR5 model. The rows list the stable states 
identified for three distinct scenarios [Wild-type (WT), TAK1 KO, and PI3K KO] and two 
environmental conditions (Unstimulated, TLR5 stimulation). White cells (value 0) denote 
negligible activation of the corresponding components (columns), whereas blue cells (value 1) 
denote substantial activation. Inputs are highlighted in green, phenotypical nodes are in gray, and 
the transcription factors induced during T cell activation are in yellow. 
 
 
 
 
 
 
 
 
  
Fig. 5. The TCR+TLR5 merged model.  The merged model encompasses 128 nodes, including 
three externally controlled inputs (TLR5, TCR, and CD28) and six phenotypic nodes (bottom). 
The pink nodes belong to the original TCR model, the blue nodes belong exclusively to the original 
TLR5 model, and the yellow nodes are shared between the two models. Green arrows represent 
activation events, whereas red, blunt-end arcs denote inhibition events. 
 
 
  
Fig. 6. Computation of the stable states for the TCR + TLR5 merged model. The rows list the 
stable states identified for three distinct scenarios [Wild-type (WT), PKC KO, and PI3K KO) and 
three environmental conditions (Unstimulated, TCR + CD28 stimulation, and TCR + TLR5 
stimulation). White cells (value 0) denote negligible activation of the corresponding components 
(columns), whereas blue cells (value 1) denote substantial activation. Inputs are highlighted in 
green, phenotypical nodes are in grzy, and the transcription factors induced during T cell activation 
are in yellow. 
 
 
 
 
 
 
 
  
Fig. 7. Experimental assessment of AP-1, NF-кB, and CREB activities. We used flow 
cytometry to evaluate the phosphorylation of c-Jun, p65, and CREB1, as a measure of the 
activation of AP-1, NF-кB, and CREB, respectively. Naive CD4+ T cells were left unstimulated 
or were stimulated under the indicated conditions for 1 hour (to measure p65 and CREB1 
activation) or 3 hours (to measure c-Jun activation). The mean fluorescence intensify (MFI) values 
for the indicated phosphoproteins were determined by flow cytometry The P values obtained by 
the Kruskal-Wallis test are indicated above the error bars, which correspond to the SEM. Each 
experiment was repeated at least three times with independent biological samples. 
